Hep C Virus - Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study resul

Combination therapy with SCH-503034 HCV Protease Inhibitor & PegIntron in Non-Responders: phase !b study resul
National AIDS Treatment Advocacy Project - In this study we compared the anti-HCV activity of SCH 503034 in combination with PEG-Intron vs SCH 503034 or PEG-Intron alone in HCV-1 PEG-Intron non-responders. Kenilworth, NJ SCH 503034 is a novel HCV protease inhibitor that delivers potent antiviral activity in